BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 17727803)

  • 21. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilar insulins.
    Heinemann L
    Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The state of the art in the development of biosimilars.
    McCamish M; Woollett G
    Clin Pharmacol Ther; 2012 Mar; 91(3):405-17. PubMed ID: 22318617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hearing shines spotlight on biosimilar controversies.
    Mullard A
    Nat Rev Drug Discov; 2010 Dec; 9(12):905-6. PubMed ID: 21119720
    [No Abstract]   [Full Text] [Related]  

  • 29. Industry views of biosimilar development in Japan.
    Horikawa H; Tsubouchi M; Kawakami K
    Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Worldwide experience with biosimilar development.
    McCamish M; Woollett G
    MAbs; 2011; 3(2):209-17. PubMed ID: 21441787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Biosimilars": towards fewer obstacles to their use.
    Prescrire Int; 2015 Mar; 24(158):80-1, 83. PubMed ID: 25897464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.
    Tamilvanan S; Raja NL; Sa B; Basu SK
    J Drug Target; 2010 Aug; 18(7):489-98. PubMed ID: 20192653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The protein science of biosimilars.
    Kuhlmann M; Covic A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v4-8. PubMed ID: 16959791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 40. Biosimilars--science, status, and strategic perspective.
    Kresse GB
    Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.